{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["darolutamide"]],"indication":"de novo metastatic prostate cancer, vulnerable functional ability","name":"PEACE6-Vulnerable","nct_id":"NCT04916613","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=peace6-vulnerable-nct04916613. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"GETUG-AFU 40","arms":[{"description":"ADT + darolutamide 600 mg po bid","label":"ADT + darolutamide","type":"EXPERIMENTAL"},{"description":"ADT + placebo po bid","label":"ADT + placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":["Bayer"],"completion_date":{"date":"2037-09","type":"ESTIMATED"},"conditions":["Prostate Cancer Metastatic"],"enrollment":{"count":300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Darolutamide 300 mg","otherNames":["Nubeqa®"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Androgen deprivation therapy","otherNames":["ADT"],"type":"DRUG"}],"last_update":"2026-04-28","lead_sponsor":"UNICANCER","official_title":"A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Radiographic progression-free survival","timeFrame":"From randomisation to radiographic progression or death, up to 18 months"}],"references":[],"start_date":{"date":"2022-04-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","url":"https://clinicaltrials.gov/study/NCT04916613"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/peace6-vulnerable-nct04916613"}